Recent Updates
Atezolizumab Adds No Survival Benefit to BCG for High-Risk NMIBC
In the ALBAN trial, adding atezolizumab to BCG did not improve event-free survival and increased side effects.
The ALBAN trial, a large international study, aimed to test whether combining atezolizumab, an immunotherapy targeting programmed death-ligand 1 (PD-L1), with standard Bacillus Calmette-Guérin (BCG) therapy could improve outcomes for patients with high-risk, non–muscle-invasive bladder cancer (NMIBC). Unfortunately, the trial found no significant survival benefit with the combination therapy compared to BCG alone.
Among the 517 patients enrolled, those in the atezolizumab-plus-BCG group experienced similar event-free survival rates to those receiving BCG alone, with a hazard ratio of 0.98. This means the addition of atezolizumab did not reduce the risk of cancer recurrence or progression. Notably, the study also showed that patients receiving the combination therapy had higher rates of side effects, including severe treatment-related adverse events.
For patient navigators, these findings reinforce BCG therapy as the standard treatment for high-risk NMIBC. Although immunotherapy has shown promise in other cancers, its role in NMIBC remains unclear. Future research will focus on identifying biomarkers that can predict which patients might respond better to therapies like atezolizumab.
While the ALBAN trial didn’t change the current treatment landscape, it highlights the importance of personalized care. Navigators can support patients by ensuring they understand their treatment options and helping them manage potential side effects. For those asking about immunotherapy, it’s important to explain that while exciting advances are happening, not all approaches work for every cancer type.
By staying informed about trials like ALBAN, patient navigators can provide accurate guidance, empowering patients to make confident decisions about their care paths.
Reference
Roupret M, Bertaut A, Pignot G, et al. ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC). Ann Oncol. 2026;37(1):44-52. Online ahead of print.
The ALBAN trial, a large international study, aimed to test whether combining atezolizumab, an immunotherapy targeting programmed death-ligand 1 (PD-L1), with standard Bacillus Calmette-Guérin (BCG) therapy could improve outcomes for patients with high-risk, non–muscle-invasive bladder cancer (NMIBC). Unfortunately, the trial found no significant survival benefit with the combination therapy compared to BCG alone.
Among the 517 patients enrolled, those in the atezolizumab-plus-BCG group experienced similar event-free survival rates to those receiving BCG alone, with a hazard ratio of 0.98. This means the addition of atezolizumab did not reduce the risk of cancer recurrence or progression. Notably, the study also showed that patients receiving the combination therapy had higher rates of side effects, including severe treatment-related adverse events.
For patient navigators, these findings reinforce BCG therapy as the standard treatment for high-risk NMIBC. Although immunotherapy has shown promise in other cancers, its role in NMIBC remains unclear. Future research will focus on identifying biomarkers that can predict which patients might respond better to therapies like atezolizumab.
While the ALBAN trial didn’t change the current treatment landscape, it highlights the importance of personalized care. Navigators can support patients by ensuring they understand their treatment options and helping them manage potential side effects. For those asking about immunotherapy, it’s important to explain that while exciting advances are happening, not all approaches work for every cancer type.
By staying informed about trials like ALBAN, patient navigators can provide accurate guidance, empowering patients to make confident decisions about their care paths.
Reference
Roupret M, Bertaut A, Pignot G, et al. ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC). Ann Oncol. 2026;37(1):44-52. Online ahead of print.
